Psychotherapy

Neuronetics Reports Record Fourth Quarter and Record Full Year 2023 Financial and Operating Results

Retrieved on: 
Tuesday, March 5, 2024
Social media, TMS, Transcranial magnetic stimulation, Telephone, Marketing, SSM Health, Webcast, Health, Neuronetics, Patient, Policy, Ferdinand Magellan, Knowledge, Psychotherapy

For the period ended December 31, 2023 and 2022, the Company shipped 205 and 213 systems, respectively.

Key Points: 
  • For the period ended December 31, 2023 and 2022, the Company shipped 205 and 213 systems, respectively.
  • Gross margin for the full year 2023 were 72.5%, a decrease of approximately 380 basis points from the full year 2022 gross margin of 76.3%.
  • Operating expenses during the full year 2023 was $82.3 million, a decrease of $2.5 million, or 2.9% compared to $84.8 million in the full year 2022.
  • See the accompanying financial table that reconciles EBITDA, which is a non-GAAP financial measure, to net loss.

GH Research Reports Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, February 29, 2024
PD, Research, New Drug Application, TRD, GHRS, FDA, BDII, Food, EPO, Rat, Psychiatry, Patent, PPD, Patient, IDR, DSM-IV codes, Clinical trial, Insurance, Psychotherapy, G&A, MDD, IND, European Patent Convention, Pharmaceutical industry

DUBLIN, Ireland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the year ended December 31, 2023, and provided updates on its business.

Key Points: 
  • DUBLIN, Ireland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the year ended December 31, 2023, and provided updates on its business.
  • As announced in November 2023, both trials were recruiting slower than anticipated, in part due to the closure, for business reasons, of one of the two sites activated in each trial.
  • Subsequently, we have implemented measures to strengthen recruitment of both trials, including the addition of further clinical trial sites.
  • For the trial in patients with PPD (GH001-PPD-203), we now expect completion and availability of top-line data in the third quarter of 2024.

Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder

Retrieved on: 
Wednesday, February 28, 2024
Psychotherapy

MELBOURNE, Australia and NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology company, is pleased to announce positive topline results from its Phase 2 Psi-GAD1 clinical trial of psilocybin in generalised anxiety disorder (GAD). The trial met its primary endpoint, demonstrating a large clinical effect in the psilocybin treatment group over the placebo group.

Key Points: 
  • Newly developed and formulated PSX-001 psilocybin drug product has been finalised - cGMP manufacture for clinical trial supply underway.
  • Incannex to submit an Investigational New Drug (IND) application with U.S. Food and Drug Administration (FDA) to proceed to a multi-site Phase 2B trial.
  • MELBOURNE, Australia and NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology company, is pleased to announce positive topline results from its Phase 2 Psi-GAD1 clinical trial of psilocybin in generalised anxiety disorder (GAD).
  • The trial met its primary endpoint, demonstrating a large clinical effect in the psilocybin treatment group over the placebo group.

Hightop Health partners with Roots Behavioral Health

Retrieved on: 
Thursday, February 22, 2024
Mental Health, Health, Acquisition, Mental health, Multimedia, MD, SVP, Culture, RBH, Patient, Psychotherapy, Root, Nursing

Hightop Health, a premier outpatient mental health platform, today announced the acquisition of Roots Behavioral Health.

Key Points: 
  • Hightop Health, a premier outpatient mental health platform, today announced the acquisition of Roots Behavioral Health.
  • View the full release here: https://www.businesswire.com/news/home/20240222298858/en/
    Brent Turnipseed, MD, founded Roots Behavioral Health with his wife in 2016.
  • (Photo: Business Wire)
    Roots Behavioral Health (RBH) was founded in 2016 by husband-and-wife team Brent Turnipseed, MD, and Andrea Turnipseed, LCSW-S, to address a pressing need for affordable and accessible behavioral healthcare in the Austin area.
  • “Our goal is not to partner with any and all mental health practices,” said Rob Butler, Founder and CEO of Hightop Health.

Numinus Wellness Congratulates MindMed on Positive Results from Phase 2B Clinical Trials of MM120 for Generalized Anxiety Disorder

Retrieved on: 
Friday, March 8, 2024
Anxiety, Research, MindMed, FDA, TSX, GAD, Clinical trial, Psychotherapy, Pharmaceutical industry

Based on initial clinical data from the Phase 2b trial and the significant unmet medical need in treating GAD, the U.S. Food & Drug Administration ("FDA") has designated MM120 for GAD as a breakthrough therapy.

Key Points: 
  • Based on initial clinical data from the Phase 2b trial and the significant unmet medical need in treating GAD, the U.S. Food & Drug Administration ("FDA") has designated MM120 for GAD as a breakthrough therapy.
  • Numinus' Cedar Clinical Research Draper Utah research clinic was among the highest enrolling sites for the study, with its clinic at Murray, Utah, also participating.
  • Dr. Reid Robison, Numinus' Chief Clinical Officer and Dr. Paul Thielking, Chief Science Officer, were Principal Investigators.
  • "We look forward to continuing to work with MindMed as it advances its important research into MM120.

Allegheny Health Network Launches New Program for the Treatment of Insomnia

Retrieved on: 
Tuesday, March 5, 2024
Caregiver, Allegheny Health Network, NIH, Sleep apnea, Thought, Sleep, Belgrave, Patient, Relaxation, Health, American College, Arousal, MPH, Cognitive behavioral therapy, Psychotherapy, AHN, Physician, CBTI, Nursing

PITTSBURGH, March 5, 2024 /PRNewswire-PRWeb/ -- Allegheny Health Network (AHN) today announced that it has launched a new, evidence-based treatment program to help patients with insomnia improve their sleep quality and quantity without the use of medication. Supported by grant funding from the Richard King Mellon Foundation, the Cognitive Behavioral Therapy for Insomnia (CBTI) program at AHN is a blended effort between the AHN Primary Care Institute, AHN Psychiatry & Behavioral Health Institute and Highmark Health.

Key Points: 
  • PITTSBURGH, March 5, 2024 /PRNewswire-PRWeb/ -- Allegheny Health Network (AHN) today announced that it has launched a new, evidence-based treatment program to help patients with insomnia improve their sleep quality and quantity without the use of medication.
  • Supported by grant funding from the Richard King Mellon Foundation, the Cognitive Behavioral Therapy for Insomnia (CBTI) program at AHN is a blended effort between the AHN Primary Care Institute, AHN Psychiatry & Behavioral Health Institute and Highmark Health.
  • Patients may access the AHN CBTI program via the AHN Primary Care Institute, AHN Psychiatry & Behavioral Health Institute or the AHN Medicine Institute.
  • "Adding CBTI as a whole-person approach to care at AHN is another important step to reinventing health with our Living Health strategy."

Psychedelics set to be the revolutionary treatments in pscyhiatry- Thelansis Knowledge Partners

Retrieved on: 
Thursday, February 22, 2024
Knowledge, DSM-IV codes, Esketamine, TRD, Major depressive disorder, Drug development, TAS, USFDA, Psilocybin, MDMA, Psychiatry, CNS, Patient, Acute stress disorder, PTSD, Polypharmacy, Psychotherapy, MDD, KOL, Research, Central nervous system disease, Pharmaceutical industry

Availability of psychedelic(s) with few administrations in a year and offering high remission rate could change the treatment pathway for these patients."

Key Points: 
  • Availability of psychedelic(s) with few administrations in a year and offering high remission rate could change the treatment pathway for these patients."
  • According to an interviewed U.S.-based neurologist by Thelansis – "We desperately need disease-modifying treatments for many neurodegenerative conditions.
  • As psychedelics would be beneficial for treatment-nonresponders or severe patients, the commercial opportunities are multiple for in-pipeline psychedelic therapies.
  • What is the probable opportunity for Psychedelics (e.g., psilocybin, MDMA) to address the unmet needs of other TAs?

Psychedelics set to be the revolutionary treatments in pscyhiatry - Thelansis Knowledge Partners

Retrieved on: 
Thursday, February 22, 2024
Knowledge, DSM-IV codes, Esketamine, TRD, Major depressive disorder, Drug development, TAS, USFDA, Psilocybin, MDMA, Psychiatry, CNS, Patient, Acute stress disorder, PTSD, Polypharmacy, Psychotherapy, MDD, KOL, Research, Central nervous system disease, Pharmaceutical industry

Availability of psychedelic(s) with few administrations in a year and offering high remission rate could change the treatment pathway for these patients."

Key Points: 
  • Availability of psychedelic(s) with few administrations in a year and offering high remission rate could change the treatment pathway for these patients."
  • According to an interviewed U.S.-based neurologist by Thelansis – "We desperately need disease-modifying treatments for many neurodegenerative conditions.
  • As psychedelics would be beneficial for treatment-nonresponders or severe patients, the commercial opportunities are multiple for in-pipeline psychedelic therapies.
  • What is the probable opportunity for Psychedelics (e.g., psilocybin, MDMA) to address the unmet needs of other TAs?

Innerwell expands insurance access to innovative mental health treatment and announces the launch of Innerwell Insights, its AI-driven behavioral coaching platform

Retrieved on: 
Thursday, February 15, 2024
Ferdinand Magellan, Blue Shield, EMDR, Machine learning, Patient, Psychotherapy, AI, Insurance, Nursing

NEW YORK, Feb. 15, 2024 /PRNewswire-PRWeb/ -- Innerwell, a first-of-its-kind mental health platform, has announced its expansion into in-network care with four major insurance partners in California, as well as two insurance partners in New York. This move extends the reach of Innerwell's range of innovative treatments, including traditional psychiatry and talk therapy alongside specialized modalities like ketamine treatment and EMDR.

Key Points: 
  • NEW YORK, Feb. 15, 2024 /PRNewswire-PRWeb/ -- Innerwell , a first-of-its-kind mental health platform, has announced its expansion into in-network care with four major insurance partners in California, as well as two insurance partners in New York.
  • This move extends the reach of Innerwell's range of innovative treatments, including traditional psychiatry and talk therapy alongside specialized modalities like ketamine treatment and EMDR.
  • With millions now eligible for in-network coverage, Innerwell aims to expand access to cutting-edge mental health treatments with these new insurance partnerships.
  • Later this year, the company plans to launch its patient mental health platform 2.0, a revolutionary step utilizing AI to optimize patient outcomes.

‘Self-love’ might seem selfish. But done right, it’s the opposite of narcissism

Retrieved on: 
Sunday, February 11, 2024
Love, Social media, Philosophy, Eating, Self-acceptance, Psychology, Ethics, Malignancy, Smoking, Language, Applied mechanics, Psychotherapy, Self-love, Self-assessment, Ancient Greek

Some may argue this social media generation does not seem to struggle with loving themselves.

Key Points: 
  • Some may argue this social media generation does not seem to struggle with loving themselves.
  • But is the look-at-me-ism so easily found on TikTok and Instagram the kind of self-love we need in order to flourish?
  • The language of positive psychology can be – and often is – appropriated for all kinds of self-importance, as well as cynical marketing strategies.

Philosophy and self-love

  • Psychology researcher Li Ming Xue and her colleagues, exploring the notion of self-love in Chinese culture, claim “Western philosophers believe that self-love is a virtue”.
  • In the Christian tradition and in much European philosophy, says philosopher Razvan Ioan, self-love is condemned as a profoundly damaging trait.
  • In particular, Aristotle.
  • Read more:
    Friday essay: 3 ways philosophy can help us understand love

Bar too high?

  • Aristotle might set the bar too high.
  • Many psychologists claim self-love is important for adopting the kind and compassionate self-perception crucial for overcoming conditions that weaponise self-criticism, like clinical perfectionism and eating disorders.
  • For this reason, a compassionate form of self-love is often necessary to follow Socrates’ advice to “know thyself”, says philosopher Jan Bransen.

Self-love ‘misguided and silly’

  • His ideas are mostly rejected by philosophers of love, but pointing out where they go wrong can be useful.
  • When you love someone, he said, you’re prepared to sacrifice your own interests for those of your beloved.
  • But he thought the idea of sacrificing your own interests made no sense – which shows, he concluded, we can’t love ourselves.
  • In pop culture, love is often depicted as a willingness to sacrifice, but ancient philosophers took a different view

Self-compassion

  • We might need this self-compassion, too, in order to admit our failures – so we can overcome our defensiveness and see clearly how we’re failing to fulfil these interests.
  • Self-love, as promoted by contemporary psychologists, means standing in a compassionate relationship to ourselves.
  • It promotes comfort with the kind of critical self-assessment that helps us grow – which leads to resilience.


Ian Robertson does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.